Literature DB >> 32678904

Actinomycin D: a new opening for an old drug.

Gaetano Finocchiaro1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32678904      PMCID： PMC7523453          DOI： 10.1093/neuonc/noaa172

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  10 in total

1.  Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group.

Authors:  Bryan Langholz; Jeffrey M Skolnik; Jeffrey S Barrett; Jamie Renbarger; Nita L Seibel; Anne Zajicek; Carola A S Arndt
Journal:  Pediatr Blood Cancer       Date:  2010-12-01       Impact factor: 3.167

2.  Reduced Expression of PROX1 Transitions Glioblastoma Cells into a Mesenchymal Gene Expression Subtype.

Authors:  Kaveh M Goudarzi; Jaime A Espinoza; Min Guo; Jiri Bartek; Monica Nistér; Mikael S Lindström; Daniel Hägerstrand
Journal:  Cancer Res       Date:  2018-08-22       Impact factor: 12.701

3.  Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study.

Authors:  Raymond J Osborne; Virginia Filiaci; Julian C Schink; Robert S Mannel; Angeles Alvarez Secord; Joseph L Kelley; Diane Provencher; David Scott Miller; Allan L Covens; Janice M Lage
Journal:  J Clin Oncol       Date:  2011-01-24       Impact factor: 44.544

4.  Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption.

Authors:  Costas D Arvanitis; Vasileios Askoxylakis; Yutong Guo; Meenal Datta; Jonas Kloepper; Gino B Ferraro; Miguel O Bernabeu; Dai Fukumura; Nathan McDannold; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-27       Impact factor: 11.205

5.  Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells.

Authors:  Mario L Suvà; Esther Rheinbay; Shawn M Gillespie; Anoop P Patel; Hiroaki Wakimoto; Samuel D Rabkin; Nicolo Riggi; Andrew S Chi; Daniel P Cahill; Brian V Nahed; William T Curry; Robert L Martuza; Miguel N Rivera; Nikki Rossetti; Simon Kasif; Samantha Beik; Sabah Kadri; Itay Tirosh; Ivo Wortman; Alex K Shalek; Orit Rozenblatt-Rosen; Aviv Regev; David N Louis; Bradley E Bernstein
Journal:  Cell       Date:  2014-04-10       Impact factor: 41.582

Review 6.  Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.

Authors:  Jann N Sarkaria; Leland S Hu; Ian F Parney; Deanna H Pafundi; Debra H Brinkmann; Nadia N Laack; Caterina Giannini; Terence C Burns; Sani H Kizilbash; Janice K Laramy; Kristin R Swanson; Timothy J Kaufmann; Paul D Brown; Nathalie Y R Agar; Evanthia Galanis; Jan C Buckner; William F Elmquist
Journal:  Neuro Oncol       Date:  2018-01-22       Impact factor: 12.300

7.  Identification of a SOX2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile.

Authors:  Daniel Hägerstrand; Xiaobing He; Maja Bradic Lindh; Saskia Hoefs; Göran Hesselager; Arne Ostman; Monica Nistér
Journal:  Neuro Oncol       Date:  2011-09-22       Impact factor: 12.300

Review 8.  p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy.

Authors:  B Rao; S Lain; A M Thompson
Journal:  Br J Cancer       Date:  2013-11-14       Impact factor: 7.640

Review 9.  Targeting the RNA Polymerase I Transcription for Cancer Therapy Comes of Age.

Authors:  Rita Ferreira; John S Schneekloth; Konstantin I Panov; Katherine M Hannan; Ross D Hannan
Journal:  Cells       Date:  2020-01-21       Impact factor: 6.600

10.  Actinomycin D downregulates Sox2 and improves survival in preclinical models of recurrent glioblastoma.

Authors:  Jessica T Taylor; Stuart Ellison; Alina Pandele; Shaun Wood; Erica Nathan; Gabriella Forte; Helen Parker; Egor Zindy; Mark Elvin; Alan Dickson; Kaye J Williams; Konstantina Karabatsou; Martin McCabe; Catherine McBain; Brian W Bigger
Journal:  Neuro Oncol       Date:  2020-09-29       Impact factor: 12.300
  10 in total
  2 in total

1.  The actinomycin D molecule docks to a hydrophilic section of the SOX2 high-mobility group (HMG) domain.

Authors:  Steven Lehrer; Peter H Rheinstein
Journal:  Neuro Oncol       Date:  2021-03-25       Impact factor: 12.300

Review 2.  Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma.

Authors:  Ioannis Ntafoulis; Stijn L W Koolen; Sieger Leenstra; Martine L M Lamfers
Journal:  Cancers (Basel)       Date:  2022-07-29       Impact factor: 6.575
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.